The Billion-Dollar Bet on Saving Sight: Bayer’s Acquisition of Perfuse Therapeutics
There’s something profoundly human about the race to cure blindness. It’s not just about restoring vision—it’s about reclaiming independence, dignity, and connection to the world. So when Bayer announced its $2.45 billion acquisition of Perfuse Therapeutics, I couldn’t help but see it as more than a corporate deal. It’s a bold wager on the future of ophthalmology, one that could reshape how we treat two of the most devastatingine diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases diseases...... diseases..
**
**
